GlassScriptPhysician profile
Pallavi Agarwal
NPI 1831249812
$3,784.86
in general payments reported to CMS, 2019-2025
30 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $436 · 2021: $666 · 2022: $419 · 2023: $567 · 2024: $509 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $700.09 | 2019-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $512.47 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.52 | 2019-2025 | Ofev, Jardiance |
| Abbvie INC. | $205.02 | 2021-2025 | Vraylar |
| Corium, LLC | $199.62 | 2022-2023 | Azstarys, Adlarity |
| Glaxosmithkline, LLC. | $196.54 | 2019-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $172.69 | 2019-2025 | |
| Pfizer INC. | $142.78 | 2021-2025 | |
| Biogen, INC. | $129.99 | 2021-2023 | Skyclarys |
| Horizon Therapeutics Plc | $115.86 | 2019-2022 | |
| Abbott Laboratories | $112.38 | 2020-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.19 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $74.50 | 2024-2025 | Cologuard Collection Kit |
| Travere Therapeutics, INC. | $71.41 | 2023-2025 | |
| Allergan, INC. | $70.77 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.16 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $55.86 | 2024 | Gemtesa |
| Almatica Pharma LLC | $55.25 | 2024 | Loreev Xr |
| Acadia Pharmaceuticals INC | $54.30 | 2019-2020 | |
| Amgen INC. | $50.72 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $39.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $36.98 | 2024 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $35.24 | 2024 | |
| Paratek Pharmaceuticals, INC. | $32.30 | 2021 | |
| Eisai INC. | $31.79 | 2025 | |
| Medtronic, INC. | $21.99 | 2025 | Inceptiv |
| Scilex Pharmaceuticals INC. | $21.85 | 2023 | Ztlido |
| Currax Pharmaceuticals LLC | $15.43 | 2025 | Contrave |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.84 | 2025 | Rexulti |
| Lundbeck LLC | $12.86 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pallavi Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.